ALX ONCOLOGY HOLDINGS INC
About ALX ONCOLOGY HOLDINGS INC
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $0
- Net income
- -$101.7M
- Total assets
- $59.0M
- Market cap
- $207.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $104.0M
- Operating income
- -$104.0M
- Income tax
- $0
- Net income
- -$101.7M
- EPS (basic)
- $-1.90
- EPS (diluted)
- $-1.90
Balance sheet
- Total assets
- $59.0M
- Current assets
- $50.7M
- Total liabilities
- $33.1M
- Current liabilities
- $24.6M
- Shareholders’ equity
- $26.0M
Cash flow
- Operating cash flow
- -$84.1M
- Investing cash flow
- $82.6M
- Financing cash flow
- $362.0K
- Net cash flow
- -$1.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $207.2M
- EPS (diluted)
- $-1.9
- Shares outstanding
- 132.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 17, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $101.7M in FY2022.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ALX ONCOLOGY HOLDINGS INC.
Write a review
News about ALX ONCOLOGY HOLDINGS INC
News & sentiment via Polygon.io
